Ory Rouvio
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
-
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 11
- Multiple Myeloma Research and Treatments 11
-
- Protein Degradation and Inhibitors 7
- Co-authors
- Tamar Tadmor (11 shared papers)Hila Magen (7 shared papers)Moshe E. Gatt (9 shared papers)Irit Avivi (9 shared papers)Yaël C. Cohen (9 shared papers)Noa Lavi (6 shared papers)Evgeni Chubar (4 shared papers)Chezi Ganzel (5 shared papers)
- Journals
- Blood (5 papers)Leukemia Research (2 papers)Journal of Cancer (1 paper)British Journal of Haematology (1 paper)Vaccine (1 paper)
- Partner nations
- IsraelUnited StatesItaly
In The Last Decade
Ory Rouvio
18 papers receiving 124 citations
Peers
Comparison fields: 5 of 37
- Hematology 71
- Genetics 38
- Oncology 51
- Molecular Biology 76
- Immunology 20
Countries citing papers authored by Ory Rouvio
This map shows the geographic impact of Ory Rouvio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ory Rouvio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ory Rouvio more than expected).
Fields of papers citing papers by Ory Rouvio
This network shows the impact of papers produced by Ory Rouvio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ory Rouvio. The network helps show where Ory Rouvio may publish in the future.
Co-authors
The 25 scholars most cited alongside Ory Rouvio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 31 | |
| 2 | 2020 | 18 | |
| 3 | 2020 | 13 | |
| 4 | 2005 | 11 | |
| 5 | 2018 | 10 | |
| 6 | 2022 | 10 | |
| 7 | 2018 | 8 | |
| 8 | 2018 | 6 | |
| 9 | 2019 | 5 | |
| 10 | 2016 | 3 | |
| 11 | 2019 | 2 | |
| 12 | 2020 | 2 | |
| 13 | 2015 | 1 | |
| 14 | 2020 | 1 | |
| 15 | 2017 | 1 | |
| 16 | 2016 | 1 | |
| 17 | 2022 | 1 | |
| 18 | 2013 | 1 | |
| 19 | 2018 | 1 |
About Ory Rouvio
Ory Rouvio is a scholar working on Hematology, Molecular Biology, Oncology, Genetics and Pathology and Forensic Medicine, having authored 19 papers that have together received 126 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), Viral-associated cancers and disorders (3 papers), Peptidase Inhibition and Analysis (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Hematology (71 citations), Genetics (38 citations), Oncology (51 citations), Molecular Biology (76 citations) and Immunology (20 citations). Ory Rouvio has collaborated with scholars based in Israel, United States and Italy. Frequent co-authors include Tamar Tadmor, Hila Magen, Moshe E. Gatt, Irit Avivi, Yaël C. Cohen, Noa Lavi, Evgeni Chubar, Chezi Ganzel, Angel Porgador and Irun R. Cohen. Their work appears in journals such as Blood, Leukemia Research, Journal of Cancer, British Journal of Haematology and Vaccine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.